Frank Lopez - Academia.edu (original) (raw)

Papers by Frank Lopez

Journal of the American Academy of Child & Adolescent Psychiatry, 2021

American Journal of Gastroenterology, 2020

Journal of Health Economics and Outcomes Research, 2016

Background: Understanding patient and caregiver preferences for treatment is important for optimi... more Background: Understanding patient and caregiver preferences for treatment is important for optimizing treatment decisions. Non-stimulant therapies are an alternative treatment option to stimulant therapy for attention-deficit/hyperactivity disorder (ADHD). Guanfacine extended release (GXR) and atomoxetine (ATX) are two non-stimulant medications approved in the United States for the treatment of ADHD. Objective: To identify non-stimulant ADHD medication attributes important to caregivers/patients. Methods: US caregivers of ADHD patients (6–17 years) and child/adolescent patients (10–17 years) completed an adaptive conjoint analysis survey. Respondents selected between hypothetical treatments with different attributes. Ordinary least-squares and hierarchical Bayes regression using Sawtooth Software were used to calculate utilities, importance ratings, and preferences. Results: 483 caregivers (mean age: 41.9 years, standard deviation [SD]: 8.7; 75% female) and 211 children/adolescents ...

American Journal of Gastroenterology, 2017

American Journal of Gastroenterology, 2018

Postgraduate Medicine, 2019

Objectives: To evaluate the duration of efficacy, safety, and tolerability of SHP465 mixed amphet... more Objectives: To evaluate the duration of efficacy, safety, and tolerability of SHP465 mixed amphetamine salts (MAS) extended-release versus placebo and immediate-release MAS (MAS IR) in adolescents with attention-deficit/hyperactivity disorder (ADHD). Methods: This phase 2, randomized, 3-period, 3-treatment crossover study compared SHP465 MAS (25/ 50 mg) with placebo and MAS IR (12.5 mg) in 13-17-year-old adolescents with ADHD having ADHD Rating Scale, Version IV (ADHD-RS-IV) total scores ≥24. A laboratory classroom served as a controlled environment during 16-hour observations, with efficacy assessed on the last day of each 7-day treatment period. The primary efficacy analysis compared SHP465 MAS with placebo on Permanent Product Measure of Performance (PERMP) total score averaged over the 16-hour postdose period using a mixed linear model. Comparisons were also conducted between MAS IR and placebo (for assay sensitivity) and between SHP465 MAS and MAS IR. PERMP problems attempted and answered correctly and ADHD symptoms based on ADHD-RS-IV; participant self-report; Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale; and Revised Conner's Parent Rating Scale scores were also evaluated. Safety and tolerability assessments included treatment-emergent adverse events and vital signs. Results: The intent-to-treat population included 84 participants. Least squares mean (95% CI) PERMP total score treatment differences significantly favored SHP465 MAS (combined 25/50 mg) over placebo for the average of all postdose assessment time points (41.26 [32.24, 50.29]; P < 0.0001) and each postdose assessment time point (all P < 0.0001). Similar results were observed for MAS IR versus placebo (all postdose assessment time points averaged: nominal P < 0.0001; each postdose assessment time point: all nominal P < 0.004). The safety and tolerability of SHP465 MAS were consistent with previous reports. Conclusions: SHP465 MAS significantly improved PERMP total scores versus placebo from 2 to 16 hours postdose in adolescents with ADHD. The safety and tolerability profile of SHP465 MAS was consistent with previous reports of SHP465 MAS in individuals with ADHD.

Drug Intelligence & Clinical Pharmacy, 1977

Drug Intelligence & Clinical Pharmacy, 1978

Cryogenic Optical Systems and Instruments XIII, 2011

The Near Infrared Camera (NIRCam) instrument for NASA&amp;amp;amp;amp;amp;amp;amp;amp;#39... more The Near Infrared Camera (NIRCam) instrument for NASA&amp;amp;amp;amp;amp;amp;amp;amp;#39;s James Webb Space Telescope (JWST) has an optical prescription which includes numerous fold mirror assemblies. The instrument will operate at 35K after experiencing launch loads at ~293K. The optic mounts must accommodate all associated thermal and mechanical stresses, plus maintain exceptional optical quality during operation. Lockheed Martin Space Systems Company (LMSSC) conceived,

Proceedings of the 9th Workshop on Performance Metrics for Intelligent Systems, 2009

ABSTRACT We propose to apply principles from the Army Evaluation Center's Mission Based Test... more ABSTRACT We propose to apply principles from the Army Evaluation Center's Mission Based Test and Evaluation (MBT&E) to Unmanned and Autonomous Systems (UAS) Test and Evaluation (T&E) in order to conduct rigorous, real-world testing based on anticipated military ...

Postgraduate medicine, 2008

To evaluate the efficacy of lisdexamfetamine dimesylate (LDX) in school-aged children with attent... more To evaluate the efficacy of lisdexamfetamine dimesylate (LDX) in school-aged children with attention-deficit/hyperactivity disorder (ADHD), using the Conners' Parent Rating Scale, Revised Short Version (CPRS-R:S) and its subscales. This was a secondary post hoc analysis of data from a placebo-controlled, double-blind, parallel-group, forced dose-escalation trial. Boys and girls aged 6 to 12 years with a primary diagnosis of ADHD were randomly assigned to LDX (30, 50, or 70 mg/d) or placebo. Improvement on the CPRS-R:S and its subscales (ADHD Index, hyperactivity, oppositional, and cognition) at 10:00 AM, 2:00 PM, and 6:00 PM was analyzed. Safety assessments included the identification of adverse events and were conducted throughout the study. Of the 290 patients randomized, 285 were included in the intent-to-treat population. Parents noted significant improvements at all 3 assessment times on the CPRS-R:S total score and for the CPRS-R:S ADHD Index, hyperactivity, and cognition ...

Review of Scientific Instruments, 2006

Two new gated x-ray imaging cameras have recently been designed, constructed and delivered to the... more Two new gated x-ray imaging cameras have recently been designed, constructed and delivered to the National Ignition Facility in Livermore, CA. These Gated X-ray Detectors are each designed to fit within an aluminum airbox with a large capacity cooling plane and are fitted with an array of environmental housekeeping sensors. These instruments are significant different from earlier generations of gated x-ray images due in parts to an innovative impendence matching scheme, advanced phosphor screens, pulsed phosphor circuits, precision assembly fixturing, unique system monitoring and complete remote computer control. Preliminary characterization has shown repeatable uniformity between imaging strips, improved spatial resolution and no detectable impendence reflections.

Pediatric Drugs, 2003

Ritalin ® LA™ (20mg) to the starting dose of Concerta ® (18mg), in a laboratory school setting fo... more Ritalin ® LA™ (20mg) to the starting dose of Concerta ® (18mg), in a laboratory school setting for the duration of an entire school day. Secondary objectives were to compare Ritalin ® LA™ 20mg with Concerta ® 36mg, and Ritalin ® LA™ and both Concerta ® doses versus placebo across the school day. Methods: Thirty-six children (29 males, 7 females), aged 6-12 years, with attention deficit hyperactivity disorder, previously stabilized on methylphenidate (MPH), completed this four-way, randomized, single-blind crossover, analog classroom study. Patients were evaluated on day 0 and randomized to receive treatment on days 7, 14, 21, and 28 (Ritalin ® LA™ 20mg, Concerta ® 18mg, Concerta ® 36mg, or placebo). Results: Swanson, Kotkin, Agler, M-Flynn and Pelham Rating Scale (SKAMP)-attention: The effect of Ritalin ® LA™ 20mg across the morning was statistically different from that of Concerta 18mg and 36mg, as demonstrated by the change in the area under the curve (AUC) during the first 4 hours (0-4) from pre-dose. AUC(0-4) for Ritalin ® LA™ was-2.48 versus-1.36 for Concerta ® 18mg (p = 0.015), and-1.55 for Concerta ® 36mg (p = 0.043). AUC(0-8) change from pre-dose for Ritalin ® LA™ was-4.48 versus-2.72 for Concerta ® 18mg (p = 0.074), and-3.24 for Concerta ® 36mg (p = 0.208). SKAMP-deportment: AUC(0-4) for Ritalin ® LA™ was-1.67 compared with-0.28 for Concerta ® 18mg (p < 0.001), and-0.55 for Concerta ® 36mg (p = 0.004). AUC(0-8) change from pre-dose for Ritalin ® LA™ was-2.81 compared with-0.82 for Concerta ® 18mg (p = 0.018), and-1.34 for Concerta ® 36mg (p = 0.078). Combined: Mean AUC(0-4) change from pre-dose for Ritalin ® LA™ was-2.05 compared with-0.78 for Concerta ® 18mg (p < 0.001),-1.01 for Concerta ® 36mg (p = 0.003). The mean AUC(0-8) change from pre-dose for Ritalin ® LA™ was-3.58 compared with-1.70 for Concerta ® 18mg (p = 0.010),-2.22 for Concerta ® 36mg (p = 0.061). Math test-attempted: Mean pre-dose score for Ritalin ® LA™ was about 73 compared with 74, 90, and 81 for Concerta ® 18mg, 36mg, and placebo, respectively. Mean AUC(0-8) change from pre-dose for Ritalin ® LA™ was 202 compared with 115 for Concerta ® 18mg (p = 0.135), 137 for Concerta ® 36mg (p = 0.265). Math test-correct: Mean pre-dose score for Ritalin ® LA™ was 68 compared with 64, 78, and 76 for Concerta ® 18mg, 36mg, and placebo, respectively. Mean AUC(0-8) change from pre-dose for Ritalin ® LA™ was 183 compared with 100 for Concerta ® 18mg (p = 0.144), and 117 for Concerta ® 36mg (p = 0.245). 1 The use of tradenames is for product identification purposes only and does not imply endorsement.

Biological Psychiatry, 2007

Objective: This 5-week, multicenter, double-blind, placebo-controlled, parallel-group investigati... more Objective: This 5-week, multicenter, double-blind, placebo-controlled, parallel-group investigation is the first fixed-dose study to evaluate efficacy and tolerability of three doses of (10, 20, or 30 mg, once daily [o.d.]) dexmethylphenidate hydrochloride (HCl) extended-release (d-MPH XR; Focalin Ò XR) across multiple settings to treat pediatric attention-deficit=hyperactivity disorder (ADHD). Results: ADHD pediatric outpatients (n ¼ 253) diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4 th edition, criteria were randomized (1:1:1:1) to receive d-MPH XR (10, 20, or 30 mg o.d.) or placebo. Treatment with d-MPH XR significantly (p < 0.001) reduced the mean score (change from baseline) on Conners'-ADHD=DSM-IV Scales (CADS) as assessed by the teacher CADS-T (dose [mean];10 mg [18], 20 mg [16.9], 30 mg [20.7]) and parents, CADS-P (dose [mean];10 mg [15.8]; 20 mg [17.8]; 30 mg [20.5]) compared to placebo (mean CADS-T [5.7]; CADS-P [4.6]). A significant (p < 0.001) proportion of patients in the three d-MPH XR treatment groups showed improvement on the clinician-rated, Clinical Global Impressions-Improvement (CGI-I) scales (10 mg [73.8%]; 20 mg [71.2%]; 30 mg [77.2 %]) and severity ratings (CGI-S) compared to the placebo group (CGI-I, 22.2%). Adverse events were mild to moderate in severity and similar to previous observations for this class of neurostimulants. Conclusion: All three doses of d-MPH XR (10, 20, or 30 mg o.d), were significantly more effective than placebo in improving ADHD symptoms as confirmed by the teacher, parent and clinician. Additionally, d-MPH XR was well tolerated and demonstrated a consistent safety profile.

Publikationsansicht. 2728819. A sensitivity investigation of mathematical models for thermal effl... more Publikationsansicht. 2728819. A sensitivity investigation of mathematical models for thermal effluent analysis. (1974). Lopez, Frank. Abstract. Thesis (MS in Nuclear Engineering)--Texas A&M University. Details der Publikation. Download, http://worldcat.org/oclc/6045726. ...

American Journal of Gastroenterology, 2021